NVE Corp. (NVEC) gave back much of its blowout first quarter in the September period. EPS was $0.65 on revenue of $5.84 million. Earnings fell 4.4% year over year and revenue fell 8.1%. That is a sharp reversal from Q1 FY27, when revenue was $11.0 million (+81%) and EPS was $1.32. No consensus figures were available, so the quarter has to be judged on its own trajectory. The central question is whether Q1 marked a new, higher plateau for a company that historically ran at $6-7 million a quarter, or whether it was mostly pulled-forward demand. The answer looks like some of both. Management's unusually explicit outlook calls for second-half revenue consistent with the first half's $16.9 million. That implies roughly $8.4 million per quarter: well above Q2, but clearly below Q1.

The quality of the quarter deserves scrutiny, because the bottom line looked better than the operations.

• Operating income fell to $3.21 million from $3.66 million a year earlier, and pretax income fell about 11%.
• Net income declined only 4%, because the tax provision dropped to roughly 14% of pretax income from about 20%, which management credited to favorable tax law changes.
• Gross margin slipped to 78% from 81.3% in Q1, as the mix shifted toward lower-margin distributor sales.
• SG&A jumped 44% year over year to $630,000 on director option grant costs.
• A 17% cut in R&D expense, attributed to staff redeployment, partly offset that increase.

Operating margin compressed to 55% from 66% in Q1 and 62% in Q4 FY26. Those are still exceptional levels, but the direction is unmistakably down. The first half remains strong: revenue rose 36%, net income rose 39% to $1.97 per diluted share, and operating cash flow reached $11.1 million versus $8.0 million a year earlier.

The call explained the shortfall in two parts. First, a large medical device customer pulled orders into Q1 from Q2 and is working through a short-term inventory adjustment. Second, and more troubling, defense product sales collapsed 95% year over year. On the Q4 FY26 call, management had expected defense sales to rise significantly this fiscal year, so that is a credibility hit on a forecast the company itself put forward.

The offset was genuinely encouraging. Distributor sales rose 67% year over year in Q2, accelerating from about 40% for the first half, and management tied that to strengthening industry conditions. Contract R&D revenue rose 25%. Those trends suggest the broader commercial and semiconductor base is improving even as NVE's concentrated customers turn lumpy.

The forward catalysts lean toward robotics. NVE launched its smallest product yet, a 0.55mm-square wafer-level chip-scale analog sensor, along with a family of seven gear sensors aimed at encoders and servos in industrial and humanoid robots. Wafer-level design wins are moving from samples toward low-thousand quantities, and expansion capacity is starting to shift from R&D to production. Investors should keep the scale in perspective. Management sized humanoid content at tens of sensors per robot at $1-2 apiece, and production timing remains uncertain. This is option value, not a near-term revenue driver.

The bear case is equally concrete. Customer concentration persists, defense visibility proved poor, and the distributor-led mix is diluting gross margin. The completed CEO transition, with Peter Eames as CEO and Dan Baker as chairman, plus a board expanded from five to seven directors, adds governance continuity, though those expanded board grants are part of the SG&A step-up.

Capital return is also near a ceiling. The $1.00 quarterly dividend matched first-half EPS of $1.97 almost exactly, and retained earnings dipped slightly from March. Payout capacity rests on continued strong cash generation and a $44.4 million cash and securities balance, up from $43.9 million in Q1.

Market context is thin this cycle, with no current price or sentiment reading available. The shares opened at $107.36 after the July report, well above the 200-day moving average of $90.01. That reflects how much enthusiasm Q1 had generated. A Q2 that falls back toward the old run rate tests that enthusiasm, and second-half guidance now does most of the work in defending it.

The bottom line is that NVE's second quarter was weaker than its EPS suggests, with a tax-rate cushion masking double-digit declines in operating and pretax income and clear margin compression. The pull-forward narrative is plausible, and accelerating distributor demand supports a recovery thesis. However, the defense miss and the gap between implied H2 run rates and Q1's peak argue for tempered expectations. Delivering roughly $8.4 million per quarter in the second half is now the bar that matters.